Literature DB >> 1991267

Expression of class I and II human leukocyte antigens by thyrocytes and lymphocytic infiltration on human thyroid tumors. An immunofluorescence study.

C Betterle1, F Presotto, A Caretto, M R Pelizzo, B Pedini, M E Girelli, B Busnardo.   

Abstract

Surgical thyroid sections from 30 papillary carcinomas (PC), six medullary carcinomas (MC), three anaplastic carcinomas (AC), two follicular carcinomas (FC), and 16 adenomas (AD) were examined with an indirect immunofluorescence technique employing different monoclonal antibodies to evaluate the expression of human leukocyte antigen (HLA)-A, B, C (Class I) and DR, DP, DQ (Class II) by thyrocytes, together with the phenotype and distribution of inflammatory cells. Ten PC and four FC were also investigated for the presence of intercellular adhesion molecule-1 (ICAM-1). In situ deposits of immunocomplexes and circulating thyroid autoantibodies were also evaluated. An increased expression of Class I antigens was found in all PC and FC, in 33% of MC and AC, and in 31% of AD. An anomalous expression of Class II antigens was observed in 70% of PC, in 50% of FC, in 33% of AC, in 19% of AD, and in none of the MC. Expression of DP or DQ was revealed only in a portion of the DR-positive glands. A reduction of microsomal autoantigen expression was found. No ICAM-1-positive thyrocytes were detected. A moderate T-lymphocytic infiltrate was noticed only in PC, where it was correlated with DR and DP and/or DQ coexpression. B-cells and natural killer cells were virtually absent. The authors speculate that the weak Class II antigens expression, together with the partial or complete loss in microsomal autoantigen and the absence of ICAM-1 by thyrocytes, may account for the limited engagement of immunocompetent cells observed in thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991267     DOI: 10.1002/1097-0142(19910215)67:4<977::aid-cncr2820670420>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Interactions between interferon gamma and retinoic acid with transforming growth factor beta in the induction of immune recognition molecules.

Authors:  R Darley; A Morris; J Passas; W Bateman
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

2.  Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.

Authors:  T Gedde-Dahl; E Nilsen; E Thorsby; G Gaudernack
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

3.  HLA-D Antigen Expression and Langerhans' Cell Infiltrates in Thyroid Tumors.

Authors:  Simon L. Raphael; Sylvia L. Asa
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

4.  Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma.

Authors:  R Heicappell; J Podlinski; H Buszello; R Ackermann
Journal:  Urol Res       Date:  1994

5.  Expression of adhesion molecule ICAM-1 (CD54) in thyroid papillary adenocarcinoma.

Authors:  M Nakashima; K Eguchi; N Ishikawa; I Yamashita; M Sakai; H Ida; Y Kawabe; K Ito; S Nagataki
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

6.  Sequential changes in MHC antigen expression induced by the v-Ki-ras oncogene.

Authors:  R L Darley; A G Morris
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

7.  An immunohistochemical study of immunological phenomena in minor salivary glands in patients with Sjögren's syndrome.

Authors:  A Caretto; P A Ostuni; F Chieco-Bianchi; B Pedini; A C Spadaccino; M Bagnasco; S Todesco; C Betterle
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

8.  Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas.

Authors:  Florian Weber; Henrik Junger; Jens M Werner; Natalia Velez Char; Carolina Rejas; Hans J Schlitt; Matthias Hornung
Journal:  Cancer Med       Date:  2019-09-27       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.